In the UK, many are starting to see a light at the end of the lockdown tunnel following the timeline for easing of restrictions being laid out. A sense of hopefulness is in the air and many are planning the return to their pre-COVID routines both in a personal and professional sense. Although, when we look toward our professional routines, should we be in such a rush to return to the way things were before? In this post, we’ll be exploring what the post-COVID world will look like for the pharmaceutical industry and healthcare professionals.
While a potential vaccine has dominated the headlines, there are other products still in the pipeline which are yet to see the light of day. Without the direct, in-person access to Healthcare Professionals (HCPs) that pharma reps usually thrive on, organisations are pivoting their efforts to digital in order to help HCPs understand how their patients can benefit from their available products. In this post we look at the current challenges and opportunities that moving to a primarily digital experience can bring to the pharma sales and education process.
Could the solution to some of the world’s health and wellness issues lie with digital health technology? Digital transformation for pharma and health companies is essential. An ageing population, a rise in chronic health conditions and increasing costs of healthcare are putting unprecedented pressure on the healthcare system in the UK and across the world. The convergence of health technology, mHealth and mobile communications is increasingly part of the solution to many of the challenges facing the health and wellness sector. Healthcare providers and pharmaceutical companies can harness this opportunity to create better outcomes for patients. Developments in personalisation and patient engagement can make a real difference. In this article, we will explore how healthcare providers are tackling today’s issues through technology, and how this innovation is changing lives.